Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Tremonton
•
June 15, 2026
•
0 Views
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026
Source: https://www.tremontonleader.com/search/?f=rss&t=article&l=50&c=news* - Read Original
Discussion (0)
Please log in to post a comment.
No comments yet. Be the first to share your thoughts!